News

Fentanyl immediate-release transmucosal medications are administered on the soft surfaces of the mouth or the nasal passages or throat where they dissolve and are absorbed. Abstral is indicated

Under the agreement, TD2 – a subsidiary of Translational Genomics Research Institute (TGen), will be the exclusive development partner for Oncoholdings’ oncology portfolio. The company plans to develop

UCB has initiated a new Phase III study assessing brivaracetam as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. The randomised, double-blind, placebo-controlled,

The ‘LifeSciencesUK’ is expected to allow biotechnology, pharmaceuticals, medical devices and diagnostics sectors to jointly funtion smoothly to better investment environment in the UK, reported Pharmacy Europe. ‘LifeSciencesUK’

The study will recruit around 200 patients and will evaluate the safety, tolerability and antiviral activity of CMX001. The primary objective of CMX001 study is to provide CMX001

Anticalins are recombinantly engineered lipocalins, endogenous low-molecular weight human proteins that naturally bind, store and transport a wide spectrum of molecules. The tie up includes an option of

Earlier, on 23 September 2010, the FDA and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of

According to the pact, Akrimax Pharma got license from NovaDel Pharma for the manufacturing and commercialization of NitroMist in North America. NovaDel Pharma’s NitroMist (nitroglycerin sublingual spray) belongs

The achievement represents progress for the collaboration, which was launched in September 2010 to develop G protein coupled receptor (GPCR)-targeted therapeutic compounds utilizing Anchor’s proprietary pepducin technology. Pepducins